Oncology

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.

Beam Therapeutics provided data on genomic rearrangement, off-target edits and from a cytokine independent growth assay to the FDA in November 2022.

Review top news and interview highlights from the week ending December 2, 2022.

Updated data from 3 of the company’s programs were presented at an R&D showcase.

There was no significant difference in OS and CR rate for patients based on household poverty and neighborhood opportunity.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CB-010 most recently demonstrated a 100% complete response rate in data presented at the EHA 2022 congress.

Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.

Paul discussed common symptoms and typical treatments for the 2 adverse events.

Review top news and interview highlights from the week ending November 25, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Sarnaik discussed several potential areas of innovation on the horizon.

The IND clearance comes after Legend terminated another clinical trial in T-cell lymphoma in July 2022.

Omidubicel’s BLA was originally accepted for priority review in August of this year.

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

The phase 1 clinical trial plans to initiate enrollment in early 2023.

Updated data from the SPEARHEAD-1 study were presented at the 2022 CTOS Annual Meeting.

The FDA has requested supplemental validation information and comparability data for the tumor-infiltrating therapy.

Review top news and interview highlights from the week ending November 18, 2022.

Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.

CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ExCellThera is in the process of the expanding the studies into new trial sites in the United States and Europe.

Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

AFNT-111 showed anti-tumor activity in NSG mouse models of breast cancer, pancreatic cancer, and colon cancer.